We observed that the migratory ability of lung cancer cells, assessed using wound-healing and Transwell assays, was significantly reduced in PYCR1-KO A549 and PYCR1-KO H1299 cells treated with EGF or TLR agonists compared with Ctrl cells (Fig. 6a–h). Here, EGF is linked to lung carcinoma.